Tuesday, November 22, 2022 10:49:21 PM
Request this pinned to the top. Thanks falconer66a
"Anti-aging may be the biggest Anavex story.
It is very, very likely that Anavex will treat glaucoma...and probably dozens of other diseases of aging.
This must be considered; evidence for such must be scrutinized.
Presently, the Anavex mechanism of action (MOA), accounting for blarcamesine’s safety and therapeutic efficacies (as demonstrated in clinical trials in various stages) is confined to blarcamesine’s “activation” of the sigma-1 receptor protein, which consequently facilitates and modulates various cellular functions. With those restored by the Anavex molecule, diseased cells then operate normally. Various CNS (central nervous system) diseases are thereby successfully treated.
Note that two of the three CNS diseases being clinically tested with blarcamesine, Parkinson’s disease dementia (PDD) and Alzheimer’s, most commonly have onsets in the later years of life. Very few children or young adults suffer from either disease. Onset of both diseases is in middle or later years in life — after later-life aging has begun.
It is not inaccurate to claim that blarcamesine activation of the sigma-1 receptor protein halts the mid-life aging processes that allow PDD and Alzheimer’s to occur. Very likely, as will be discovered when thousands of people start taking blarcamesine, the drug will prove to not only stop or reverse those two CNS diseases, but in a broader spectrum of outcomes actually slow normal aging processes.
Blarcamesine very likely will prove itself to be an effective anti-aging agent, allowing more healthful years in the last decades of life. Among other processes blarcamesine’s restoration or modulation of cellular autophagy should yield anti-aging outcomes. Autophagy, meaning “self (auto)-eating (phagy),” is the cell’s normal “housekeeping” process, where the cell “eats,” or consumes waste chemicals and cellular fragments. This allows normal cellular functions to be unperturbed by cellular wastes (such as, in Alzheimer’s beta-amyloid and tau proteins), which are cleared by autophagy.
Blarcamesine may prove to be the most significant drug to ensure healthful living in the last (and then many) years of human lives. The drug may well lengthen human “healthspans,” life-periods of normal health.
If any of this occurs, it will be incidentally discovered after many thousands have been taking the drug, for a good number of years.
But, I’m betting Dr. Missling already knows if blarcamesine yields anti-aging outcomes. He’s surely got aging data on Caenorhabditis elgans roundworms minimally dosed with the drug. Likewise with lab mice used in aging studies."
"Anti-aging may be the biggest Anavex story.
It is very, very likely that Anavex will treat glaucoma...and probably dozens of other diseases of aging.
This must be considered; evidence for such must be scrutinized.
Presently, the Anavex mechanism of action (MOA), accounting for blarcamesine’s safety and therapeutic efficacies (as demonstrated in clinical trials in various stages) is confined to blarcamesine’s “activation” of the sigma-1 receptor protein, which consequently facilitates and modulates various cellular functions. With those restored by the Anavex molecule, diseased cells then operate normally. Various CNS (central nervous system) diseases are thereby successfully treated.
Note that two of the three CNS diseases being clinically tested with blarcamesine, Parkinson’s disease dementia (PDD) and Alzheimer’s, most commonly have onsets in the later years of life. Very few children or young adults suffer from either disease. Onset of both diseases is in middle or later years in life — after later-life aging has begun.
It is not inaccurate to claim that blarcamesine activation of the sigma-1 receptor protein halts the mid-life aging processes that allow PDD and Alzheimer’s to occur. Very likely, as will be discovered when thousands of people start taking blarcamesine, the drug will prove to not only stop or reverse those two CNS diseases, but in a broader spectrum of outcomes actually slow normal aging processes.
Blarcamesine very likely will prove itself to be an effective anti-aging agent, allowing more healthful years in the last decades of life. Among other processes blarcamesine’s restoration or modulation of cellular autophagy should yield anti-aging outcomes. Autophagy, meaning “self (auto)-eating (phagy),” is the cell’s normal “housekeeping” process, where the cell “eats,” or consumes waste chemicals and cellular fragments. This allows normal cellular functions to be unperturbed by cellular wastes (such as, in Alzheimer’s beta-amyloid and tau proteins), which are cleared by autophagy.
Blarcamesine may prove to be the most significant drug to ensure healthful living in the last (and then many) years of human lives. The drug may well lengthen human “healthspans,” life-periods of normal health.
If any of this occurs, it will be incidentally discovered after many thousands have been taking the drug, for a good number of years.
But, I’m betting Dr. Missling already knows if blarcamesine yields anti-aging outcomes. He’s surely got aging data on Caenorhabditis elgans roundworms minimally dosed with the drug. Likewise with lab mice used in aging studies."
Bullish
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
